The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

In adults 60 and over, vaccine effectiveness from October 2023 to March 2024 against RSV-associated hospitalization reached 75% (95% CI 50-87), according to researchers led by Diya Surie, MD, of ...

June 17, 2025 – The FDA has expanded the use of Moderna's respiratory syncytial virus (RSV) shot to all adults, with some limits on who can get it. First approved in 2024 for people 60 or older ...

Moderna receives US FDA approval for RSV vaccine, mResvia, in adults aged 18-59 at increased risk for RSV disease. News release. Moderna. June 12, 2025.

Researchers from the CDC examined characteristics associated with RSV vaccine receipt and knowledge and attitudes relating to RSV vaccines during the first season of RSV vaccine use from October 1, ...